Cowen and BMO are the bookrunners; Canaccord, Needham, Wedbush assist
By Devika Patel
Knoxville, Tenn., Aug. 22 - Regado Biosciences, Inc. priced a $43 million initial public sale of stock with a $3.7 million greenshoe, according to a prospectus filed Thursday with the Securities and Exchange Commission. The deal was announced April 29.
The company will sell 10.75 million common shares at $4.00 apiece.
Cowen and Co. and BMO Capital Markets are the joint bookrunning managers.
Settlement is expected Aug. 27.
Proceeds will be used for the Regulate-PCI trial, for working capital and to support operations.
The biopharmaceutical company is based in Basking Ridge, N.J. It expects its shares to trade on the Nasdaq under the symbol "RGDO."
| Issuer: | Regado Biosciences, Inc.
|
| Issue: | Common stock
|
| Amount: | $43 million
|
| Greenshoe: | $3.7 million
|
| Shares: | 10.75 million
|
| Price: | $4.00
|
| Warrants: | No
|
| Bookrunners: | Cowen and Co. and BMO Capital Markets
|
| Co-managers: | Canaccord Genuity, Needham & Co. and Wedbush PacGrow Life Sciences
|
| Announcement date: | April 29
|
| Pricing date: | Aug. 22
|
| Settlement date: | Aug. 27
|
| Stock exchange: | Nasdaq: RGDO
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
